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Synopsis: Coagulation factor XII (FXII) is a key initiator of the contact pathway and kinin generation. 
We report the first peptido-mimetic complex structure for the activated protease domain βFXIIa. These 

























































































Coagulation factor XII (FXII) is a key initiator of the contact pathway which contributes to 
inflammatory pathways. FXII circulates as a zymogen, which when auto-activated forms 
factor XIIa (FXIIa). We report production of recombinant FXIIa protease domain (βFXIIaHis) 
with yields of ~1-2 mg/L of insect cell culture. A second construct utilised an N-terminal 
maltose-binding protein (MBP) fusion (MBP-βFXIIaHis). Crystal structures were determined 
for MBP-βFXIIaHis in complex with inhibitor D-Phe-Pro-Arg chloromethyl ketone (PPACK) 
and βFXIIaHis in isolation. The βFXIIaHis structure revealed the S2 and S1 pockets were 
occupied with Thr and Arg residues, respectively, from an adjacent molecule in the crystal. 
The Thr-Arg sequence mimics the P2-P1 FXIIa cleavage site residues present in the natural 
substrates prekallikrein and FXII and Pro-Arg (from PPACK) mimics the Factor XI cleavage 
site. A comparison of the βFXIIaHis structure with the available crystal structure of the 
zymogen-like FXII protease revealed large conformational changes centred around the S1 
pocket and an alternate conformation for the 99-loop, Tyr99 and the S2 pocket. Further 
comparison with activated protease structures for factors IXa and Xa, which also have residue 
Tyr99, reveals that a more open form of the S2 pocket only occurs in the presence of a 
substrate mimetic. FXIIa inhibitors EctTI and Infestin-4 have Pro-Arg and Phe-Arg P2-P1 
sequences respectively and we also describe the interactions these inhibitors form with 
βFXIIa. These structural studies of βFXIIa provide insight into substrate and inhibitor 
recognition and establish a scaffold for structure-guided drug design of novel anti-thrombotic 
and anti-inflammatory agents. 




























































































The contact activation system is initiated via auto-activation of the serine protease 
coagulation factor XII (FXII) (Weidmann et al., 2017). Activated FXII (FXIIa) cleaves 
substrates coagulation factor XI (FXI), to initiate the intrinsic pathway of coagulation, and 
prekallikrein (PK), which results in the cleavage of kininogen and bradykinin (BK) formation 
(Maas & Renne, 2018). A number of studies have established that inhibition of FXII activity 
reduces the formation of pathological thrombi without compromising physiological 
haemostasis in both murine and primate models of cardiovascular disease (Renne et al., 2012, 
Kleinschnitz et al., 2006, Matafonov et al., 2014). FXII has also been implicated in 
inflammatory pathways (Hess et al., 2017, Bender et al., 2017) and hereditary angioedema 
via identification of a gain-of-function mutation in the F12 gene (encodes FXII), which 
results in excessive formation of BK (Cichon et al., 2006).  
Natural inhibitors of the FXII protease in humans include the serpin C1INH (Nickel 
et al., 2017) and histidine rich glycoprotein (HRG) (MacQuarrie et al., 2011). FXII inhibitors 
from exogenous sources have been described including corn trypsin inhibitor (CTI) 
(Mahoney et al., 1984), Enterolobium contortisiliquum trypsin inhibitor (EcTI) (Batista et al., 
1996), Triatoma infestans infestin-4 (Campos et al., 2004) and Escherichia coli ecotin (Ulmer 
et al., 1995). CTI is widely used as an inhibitor that is selective for FXIIa and the intrinsic 
pathway of coagulation, but does not affect the extrinsic pathway. In vivo studies in animal 
models of thrombosis demonstrate infestin-4 provides protection from myocardial infarction 
and ischemic stroke without affecting hemostasis (Krupka et al., 2016). The monoclonal 
antibody 3F7 targeting the FXIIa protease domain was shown to block artificial surface-
induced thrombosis in mice and rabbits (Worm et al., 2015, Larsson et al., 2014). 
The principal protease that activates FXII is plasma kallikrein (PKa). FXII has a 
major cleavage site between residues Arg353 and Val354, generating αFXIIa and additional 
























































































in the presence of Zn2+ ions is a second route to forming αFXIIa (Ivanov et al., 2017). αFXIIa 
consists of two chains, the N-terminal heavy chain (353 residues, molecular weight (MW) 
~50 kDa) and the C-terminal light chain (243 residues, MW ~28 kDa) connected via a 
disulfide bridge between Cys340 and Cys467 (Fig. 1). A further cleavage of αFXIIa between 
residues Arg334-Asn335 produces β-factor XII (βFXIIa), which includes the light chain and 
nine residues of the heavy chain, termed the heavy chain remnant (HCR) (Pathak et al., 
2015).  
To characterise enzyme kinetics and perform protein crystallization experiments 
milligram quantities of purified βFXIIa protease are required. The insect cell-based 
Drosophila expression system (DES, Invitrogen) is a preferred choice for heterologous 
protein expression due to high yields and eukaryotic post-translational modifications. 
Trypsin-like serine proteases have a high degree of flexibility in their loop structures, which 
is known to prevent crystallization. One approach to stabilize flexible proteins is described by 
Moon et al. 2010, utilising maltose binding protein (MBP) with surface entropy reduction 
(SER) mutations as an N-terminal carrier protein to enhance protein crystallization (Moon et 
al., 2010). MBP has been reported to enhance the solubility of proteins when expressed as an 
N-terminal fusion in E. coli (Waugh, 2016, Jin et al., 2017) and mammalian expression 
systems (Reuten et al., 2016, Bokhove et al., 2016) but to date this has not been reported for 
insect cell expression systems. We describe the expression of the βFXIIa protease domain as 
a secreted MBP fusion using DES, which facilitated the crystal structure determination for 
MBP-βFXIIaHis in the active conformation in complex with peptidomimetic inhibitor D-Phe-
Pro-Arg chloromethylketone (PPACK). Another construct encoding recombinant βFXIIaHis 
without the N-terminal fusion was also purified successfully and crystallized in the absence of 
inhibitor, stabilized by a crystal contact that mimics P1 (Arg) and P2 (Thr) residues from the 
activation loop of natural substrates FXII and PK. The latter βFXIIaHis structure provides a 
rare example of a trapped protease-product complex and reveals a more open conformation of 
























































































benzamidine complex crystal structure (Fig. S1). We also utilised the βFXIIaHis crystal 
structure to examine the interactions formed with EcTI a kunitz type trypsin inhibitor and 
Infestin-4 a kazal-type inhibitor.   
 
2. Materials and methods 
All chemical and reagents were purchased from Sigma–Aldrich (Dorset, UK) unless 
otherwise stated and the purification columns used were purchased from GE Healthcare.  
2.1 Cloning and expression of βFXIIaHis and MBP-βFXIIaHis 
Based on the FXII mature protein sequence numbering, the gene fragment Asn335–
Ser596 coding for human βFXIIa was cloned into a pMT-PURO (Addgene) expression 
plasmid alone or with a noncleavable N-terminal MBP tag (Moon et al., 2010, Ullah et al., 
2008) for expression in the DES (Invitrogen, Thermo scientific Fischer, United States). To 
generate the MBP-βFXIIaHis construct, βFXIIa was fused to the MBP carrier protein with a 
five amino acid residues (AlaAlaAlaAlaSer) linker, as reported by Moon et.al., 2010 using 
the In-Fusion Advantage PCR Cloning KIT protocol (Clontech Laboratories, United States) 
and then subsequently cloned into the pMT-PURO vector. PCR primers were designed in 
order to share 15 bases of homology with the sequence at the ends of the linearized vector, 




5'ATGACCGGTACGCGTGCTCACGGTATGTTCGC3' were used for MBP and FXII, 
respectively. The PCR product encoding βFXIIaHis, was amplified using the primer pairs: 
5’GTCGAGATCTCGGACCCCGCCTCAGTCC3’;5’GCGCACGCGTGGAAACGGTGTGC
TCCCGGA3’; then digested with the appropriate restriction enzyme (BglII and MluI) and 
























































































Kit from NEB). The pMT-PURO vector has an N–terminal Drosophila homologue of the 
immunoglobulin binding chaperone protein secretion signal (BiP) to enable secretion of 
recombinant proteins and a six His-tag sequence at the C-terminus (Iwaki & Castellino, 
2008). Plasmid DNA was purified with the commercially available Sigma–Aldrich Miniprep 
Kit and ethanol precipitated prior to transfection into D. melanogaster S2 cells. The cells 
were maintained in Schneider’s Drosophila Medium (GIBCO, Fisher Scientific UK Ltd) 
supplemented with 10% fetal bovine serum (Sigma) and transfected (2-3 x 106 cells/mL, 
>95% viability 5 mL in 25 cm2 flask (Nunc, Germany)) using standard calcium phosphate 
transfection methods. Selection of pMT-PURO plasmid transfected cells was performed using 
10 µg/ml of puromycin antibiotic. Stable cells expressing the recombinant MBP-βFXIIaHis 
were confirmed based on immunoreactivity with an anti-His tag monoclonal antibody using 
western blot (Towbin et al., 1979). When cells reached a density of 9×106 cells/mL they were 
passaged by diluting 1:2 with Serum-free Express Five SFM insect culture medium  (GIBCO, 
Fisher Scientific UK Ltd) supplemented with 20 mM L-glutamine and finally cultured in a 
tissue culture shaker flask (Corning Incorporated, Corning, NY, USA) for large-scale 
expression with ≤2% serum. Protein expression was induced by supplementing culture media 
with CuSO4 to a final concentration of 0.5 mM. After 7 days at 28° C, culture media were 
harvested, centrifuged and the supernatant was used for purification of the recombinant 
protein.  
 
2.2 Protein purification of βFXIIaHis and MBP-βFXIIaHis 
Purification of recombinant βFXIIaHis was initially performed by Ni-Sepharose 
affinity (His-Excel column) chromatography, with equilibration buffer containing 50 mM 
HEPES, pH 8.3, 500 mM NaCl, 5 mM benzamidine and 10% glycerol, followed by a wash 
step with 20 mM imidazole and eluted in presence of 500 mM imidazole. The protein 
obtained from the Ni-affinity column was subject to anion exchange chromatography 
























































































10% glycerol, and buffer B containing buffer A with 1 M NaCl. Gel filtration 
chromatography (HiLoad 16/60 Superdex 75 16/60 pg) was used for the final purification 
step with buffer containing 50 mM Na-HEPES at pH 8.3, 500 mM NaCl, 5 mM benzamidine, 
10% glycerol. MBP-βFXIIaHis was initially purified using anion exchange chromatography 
with a Capto Q column with buffer A containing 20 mM Tris HCl, pH 8.0 and buffer B 
containing 20 mM Tris HCl, pH 8.0, 1 M NaCl. The second step comprised Ni-sepharose 
affinity chromatography with buffer A containing 50 mM Tris HCl, pH 8.0, 200 mM NaCl, 
20 mM imidazole and buffer B containing 50 mM Tris HCl at pH 8.0, 200 mM NaCl, 1 M 
imidazole. This construct was finally purified by gel filtration (HiLoad 16/60 Superdex 200 
16/60 pg) chromatography in buffer 20 mM Tris HCl, pH 8.0, 200 mM NaCl, 40 mM D-(+)-
maltose. The purified protein was concentrated in 20 mM Tris HCl pH 8.0, 50 mM NaCl and 
5 mM D-(+)-maltose. The yield of MBP-βFXIIaHis and βFXIIaHis varied between 1.3-2.0 
mg/L and 0.8-1.0 mg/L of culture media, respectively.   
 
2.3 Assays of FXIIa activity 
The enzymatic activity of βFXIIa was assessed by measuring the change in 
absorbance at 405 nm associated with p-nitroaniline (pNA), formed upon cleavage of the 
chromogenic substrate, S-2302 (Chromogenix, Epsom, UK). 150 nM βFXIIa was tested 
against increasing concentrations of S-2302 (0.4, 1, 2, 3, 4 and 6 mM). Commercial βFXIIa 
(Enzyme Research Laboratories, Inc.), MBP-βFXIIaHis and βFXIIaHis activity was assayed 
using 10 µL of protein added to 10 µL of substrate and diluted with 80 µL of phosphate-
buffered saline (pH 7.4) at 37 °C. The change in OD405 was monitored with a ENVISION 
multimode plate reader. An average of four independent experiments was used to determine 
the enzyme kinetics. Each substrate concentration was measured in quadruplicate (Fig. S2). 
The kinetic parameters were calculated from the experimental data using Graphpad Prism 

























































































2.4. βFXIIaHis and MBP-βFXIIaHis crystallization and structure determination 
The purified βFXIIaHis protein was concentrated to 14 mg/mL for crystallization trials 
using screens from Qiagen, Molecular Dimension and Hampton Research (Aliso Viejo, CA, 
USA) sitting drop plates. Crystals grew from conditions including 0.1 M Tris-HCl, pH 8.0 
and 1.5 M (NH4)2SO4 at 19 °C. MBP-βFXIIaHis was co-crystallized with the 
cholormethylketone based inhibitor, D-Phe-Pro-Arg-chloromethylketone (PPACK), which 
covalently modifies the Ser195 and His57 residues (Bode et al., 1989). The MBP-βFXIIHis-
PPACK complex was prepared by adding a 10-fold excess of PPACK and incubating the 
sample at 4 °C overnight. The crystallization of the MBP-βFXIIaHis-PPACK complex was 
carried out using two different protein concentrations, 8 mg/mL and 6 mg/mL. Crystals of 
MBP-βFXIIaHis-PPACK suitable for data collection were grown in 0.1 M sodium citrate, pH 
5.6 with 10% PEG 4000 and 0.15 M MgCl2 at 19 °C. Crystals obtained for both MBP-
βFXIIHis-PPACK and βFXIIaHis were harvested, cryo-protected in the crystallization solution 
with 25% glycerol and flash cooled in liquid nitrogen. X-ray diffraction data were collected at 
the beamline I04 at Diamond Light Source, UK for both βFXIIaHis and MBP-βFXIIaHis-
PPACK, which diffracted to resolutions of 2.54 Å and 4 Å, respectively. For MBP-βFXIIaHis-
PPACK crystal, diffraction data were processed with XDS (Kabsch, 2010) then scaled and 
merged with AIMLESS (Evans & Murshudov, 2013). The structure was determined by 
molecular replacement using PHASER (McCoy et al., 2007) from the CCP4 suite with search 
templates of the FXII protease domain crystal structure (PDB code: 4XDE) and the structure 
of MBP (PDB code: 1HSJ). For βFXIIaHis the diffraction data were processed with XIA2-
DIALS (Evans, 2006, Winter et al., 2018) and the structure was determined using molecular 
replacement with one molecule in the asymmetric unit. High quality electron density maps 
resulted and model building was performed with Coot (Emsley & Cowtan, 2004) and refined 

























































































2.5 Interaction of βFXIIaHis and EcTI 
2.5.1 Gel filtration  
EcTI was purified as previously described (Batista et al., 1996).  βFXIIaHis was 
concentrated to 500 µM and EcTI was added to a molar ratio of 1:1 then analyzed on 
analytical gel filtration column (Superdex 200 Increase 10/300 GL) in 20 mM Tris HCl,  pH 
8.0 and 200 mM NaCl, 5% glycerol. The EcTI-βFXIIaHis complex peak fraction was analyzed 
by SDS-PAGE. Gel filtration standards (GE healthcare) were run to calibrate the column and 
calibration curve revealed a calculated molecular weight of the EcTI-βFXIIaHis complex peak 
of ~43 kDa.  
 
2.5.2 SPR binding studies 
SPR experiments were performed on a Biacore 3000 Instrument (BIAcore) at 25 °C 
as described previously (Wong et al., 2016). EcTI was covalently coupled on a CM5 sensor 
chip using an amine coupling kit (GE healthcare) with N-hydroxysuccinimide and N-ethyl-N-
(3-(dimethylamino)propyl) carbodiimide activation. EcTI was immobilized at approximately 
300 response units (RU) and another flow cell was subjected to the identical immobilization 
procedure without EcTI protein for use as a control. The binding of βFXII to EcTI was 
studied by injecting varying concentrations of βFXII for 1200 seconds in a running buffer (20 
mM HEPES buffer, pH 7.4, 150 mM NaCl, 50 µM EDTA, 0.005% polysorbate 20) at a flow 
rate of 50 µL/min. To assess any nonspecific binding, the analyte βFXIIa (both commercial 
βFXIIa and recombinant βFXIIaHis) was also injected over the control flow cell. Binding 
curves were analyzed on the basis of the SPR RU recorded for each analyte protein 
concentration and data were processed with an appropriate fitting model using the BIA 


























































































2.5.3 Molecular docking  
Molecular docking was performed using CLUSPRO (Kozakov et al., 2017) as 
described previously (Hamad et al., 2017) and utilized the βFXIIaHis crystal structure and the 
available crystal structure of EcTI (Protein Data Bank (PDB) code 4J2Y) and infestin-4 (PDB 
code 2ERW). Molecular graphics and figures were created using PyMOL.  
 
3. Results 
3.1 Two recombinant forms of the active FXII protease 
Constructs for the MBP-βFXIIaHis fusion and isolated protease domain βFXIIaHis (Fig. 1) 
were expressed in Schneider 2 (S2) cells using the pMT-PURO vector and subsequently 
purified from culture media using affinity, ion exchange and size exclusion chromatography. 
SDS-PAGE gels under reducing conditions revealed the purified βFXIIaHis migrated as single 
band of ~30 kDa and MBP-βFXIIaHis as two bands of ~30 kDa and ~40 kDa, corresponding 
to βFXIIa and MBP, respectively, illustrating that during the purification the MBP-βFXIIaHis 
activation loop has been cleaved.  
To characterize the catalytic activity of MBP-βFXIIaHis, the hydrolysis of 
chromogenic substrate S-2302 was monitored at 405 nm. The kinetic parameters for 
recombinant MBP-βFXIIaHis, αFXIIa and βFXIIa were calculated from the initial reaction 
rates as a function of the concentration of S-2302 and the Michaelis constant Km for MBP-



























































































3.2 Crystal structure of βFXIIaHis 
βFXIIaHis crystallized in the tetrahedral space group P41212 and data were collected to 2.54 Å 
resolution with one molecule in the asymmetric unit. The crystal structure of βFXIIaHis spans 
residues Asn335-Ser596 (native FXII sequence numbering) with high-quality electron density 
and crystallographic refinement statistics (Table 2, Fig. S3). Our cloning strategy using the 
MluI restriction site resulted in the recombinant βFXIIaHis having four extra residues at the C-
terminus prior to the His-tag with sequence Thr1-Arg2-Thr3-Gly4-(6X)His (Fig. 1). We have 
followed a chymotrypsin-based numbering system throughout for FXII residues unless 
otherwise indicated and the C-terminal non-native amino acids are numbered in superscript 
(i.e. Thr1) prior to the His-tag. Unexpectedly, Thr1-Arg2 was observed in the electron density 
maps forming a crystal contact, whereas the remaining C-terminal residues Thr3-Gly4-
(6X)His were absent (Fig. 2A, S3). The Arg2 side chain is observed in the S1 binding pocket 
and its guanidinium group forms the characteristic salt bridge to the Asp189 carboxylate (Fig. 
2B and S3). The Thr1 side chain projects into the S2 pocket, formed by side chains of His57, 
Tyr99, Phe94, Pro96 and Gln60 and the Thr1 main chain carbonyl forms a hydrogen bond to 
the side chain of Gln192 (Fig. 2B). FXII residue Gly216 from the S2 pocket also forms two 
hydrogen bonds to the main chain of Ser244 from the crystal contact which are characteristic 
S2 pocket interactions for bound peptide mimetic P3 residues observed in other protease 
complex crystal structures (Kristensen et al., 2016, Bode et al., 1989). Thus the βFXIIaHis 
structure likely represents an autoproteolytic cleavage of the Arg2-Thr3 peptide bond to 
produce a crystal contact that presents a product complex with the C-terminal Arg2 
carboxylate forming electrostatic interactions with the βFXIIaHis oxyanion hole. A 
superposition of the recombinant βFXIIaHis structure with the plasma purified βFXIIa-
benzamidine complex structure (Dementiev et al., 2018) illustrates key differences arise in 


























































































3.3 Comparison of βFXIIaHis with FXII zymogen protease structures 
We have previously reported two zymogen-like crystal structures for the FXII protease 
spanning the protease domain alone (amino acids 354 to 596) (Pathak et al., 2015). These are 
termed (i) FXIIc (PDB code: 4XDE), which corresponds to a construct where the N-terminus 
is blocked by addition of two extra amino acids Arg-Ser and has very low enzymatic activity 
and (ii) FXIIac, (PDB code: 4XE4) which has the native N-terminal Val354 residue and 10-
fold higher enzyme activity compared to FXIIc but 1000-fold lower activity compared to 
βFXIIa. FXIIac is lacking the additional N-terminal residues of the HCR found in βFXIIa, 
which we speculated are required for efficient catalytic activity (Pathak et al., 2015). 
Comparison of βFXIIaHis with FXIIc reveals the expected major differences in the 
conformation of the 140-loop (also termed the autolysis loop), 180-loop and 220-loop as is 
typical for trypsin-like serine proteases (Fig. 2C). In βFXIIaHis, the 140-loop forms 
interactions with the C-terminal β-barrel, which is in contrast to the 140-loop that interacts 
with the N-terminal β-barrel in both the FXIIc and FXIIac structures. 
Additional changes not previously observed are the movement of the 99-loop away 
from the catalytic serine in βFXIIaHis and the Tyr99 sidechain has an alternate conformation 
compared to the FXIIc zymogen protease structure. The consequence is the Tyr99 sidechain 
moves away from the close packing interaction with His57 and thus opens up the S2 pocket in 
βFXIIa (Fig. 2D,E), which notably comes at the expense of the S3 pocket as the Tyr99 
sidechain partially occludes this by packing against Trp215.  
 
3.4 βFXIIa surface charge features 
We have previously observed ridges of negative charge (termed R1 and R2) in the FXIIc 
structure surrounding the catalytic residues (Pathak et al., 2015). A comparison of FXIIc with 
the active βFXIIaHis structure reveals a substantial re-arrangement of charge at the R2 ridge 
























































































barrel closer to the S1 pocket and contributes to the negative charge flanking the region of the 
S1' pocket together with residue Asp60A (Fig. 3A and B). The 140-loop is known to 
contribute to the interaction of proteases with serpins (Gong et al., 2015, Baglin et al., 2002) 
and thus the differences in this region observed between FXIIa and proteases such as FXIa 
and thrombin from the extrinsic pathway may contribute to the selectivity of inhibitor binding 
which is examined below. 
Another distinctive feature observed in the zymogen-like FXIIc structure is the 
hydrophobic H1 pocket, which is positioned at the centre of the N-terminal β-barrel and 
opposite to the S1 pocket. In the βFXIIaHis structure the H1 pocket is closed due to the 
position of Trp35, which forms a lid on the pocket and this is likely to be the dominant 
conformation (Fig. 3A).  
 
3.5 MBP-βFXIIaHis-PPACK crystal structure 
We next sought to determine the structure of a peptide mimetic complex and utilised 
the commercially available inhibitors PCK (Pro-Phe-Arg) and PPACK (Phe-Pro-Arg). These 
did not co-crystallize with βFXIIaHis so we engineered the MBP fusion construct to facilitate 
structure determination with inhibitors. MBP-βFXIIaHis crystals were obtained through co-
crystallization only with the PPACK inhibitor and the structure was determined by molecular 
replacement. Two copies of the MBP-βFXIIaHis fusion were placed in the resulting high-
quality electron density map and the refined model (Table 2) showed PPACK bound to the 
active site, and the FXII Asn74 N-linked glycan residues are also modelled (Fig. S3). Fig. 4A 
shows the overall structure of the MBP-βFXIIaHis fusion with the βFXIIaHis protease domain 
(coloured as a rainbow) positioned on top of the MBP (colored in green). The amino acid 
linker of sequence AlaAlaAlaAlaSer connecting the C-terminus of MBP to the N-terminus of 
























































































flexible (shown as a black dotted line). The 5 amino acids from the HCR fragment including 
the Cys340-Cys467 disulfide are also observed (Fig. 4A).  
Unexpectedly multiple interactions are formed between MBP and βFXIIaHis 
extending over a surface area of 654.8 Å2, (calculated using PISA) (Fig. 4B). For both copies 
of MBP-βFXIIaHis the same organisation of MBP and βFXIIaHis is observed and is 
superposable with an r.m.s.d. of 0.688 Å (for 614 C-α atoms). This MBP-βFXIIaHis interface 
occurs between three irregular loops from the FXII protease domain β-barrels and helices α2, 
α12 of MBP. From MBP helix α2 Lys46 forms a salt bridge to Asp111 from FXII, MBP 
Lys42 forms hydrogen bonds to the main chain carbonyl groups of residues Glu78 and Cys80 
and MBP Gln49 (helix α2) forms a hydrogen bond to the carbonyl of FXII Leu114  (Fig. 4B). 
A second series of interactions originates from MBP helix α12 with a salt bridge between 
MBP Arg354 and FXII Glu71 and hydrogen bonding interactions formed between the side 
chain groups of MBP Asn349 and Thr345 with the main chain nitrogen of FXII Arg24 and 
the side chain of Tyr117, respectively. The MBP Tyr341 side chain forms a hydrophobic 
interaction with FXII Pro116, MBP Asp207 forms a salt bridge to FXII Arg72 and the MBP 
Asn150 side chain hydrogen bonds to the FXII Glu78 side chain. These interactions result in 
the FXII protease covering the entrance to the MBP pocket where maltose binds and may 
explain why this additive was required for the purification and crystallization experiments. 
In the MBP-βFXIIaHis-PPACK structure, the Arg-Pro residues form characteristic 
interactions with the FXIIa S1 and S2 pockets as observed in the thrombin complex crystal 
structure, however, the P3 PPACK Phe residue projects away from the protease and is 
involved in a crystal contact. This differs from the thrombin-PPACK complex where the Phe 



























































































3.6 The complex of βFXIIaHis with inhibitor EcTI  
We next chose to characterise whether the recombinant insect cell expressed 
βFXIIaHis would interact with a kunitz type protease inhibitor and perform a comparison with 
the plasma purified βFXIIa, which will have a larger glycan structure. EcTI is a trypsin 
inhibitor derived from the plant Enterolobium contortisiliquum, which has been reported as 
inhibiting FXIIa activity and a crystal structure of EcTI in complex with trypsin is available 
(Zhou et al., 2013). To characterise the βFXIIa–EcTI complex gel filtration (Superdex 200 
Increase) chromatography was performed with an equimolar mixture of βFXIIaHis and EcTI, 
with the elution profile shown in Fig. 5A. This revealed a βFXIIaHis-EcTI complex of 
approximately 43 kDa with an excess of EcTI identified as a separate peak (~20 kDa) 
confirmed by SDS-PAGE of the resulting fractions (Fig. 5A).   
Next, surface plasmon resonance (SPR) was performed to quantify the βFXIIaHis-
EcTI binding. As shown in Fig. 5B, SPR binding curves demonstrated concentration-
dependent binding. The data were fitted using the 1:1 binding model with mass transfer to 
derive values of KD, ka and kd. The KD, ka and kd for EcTI binding to the plasma purified 
βFXIIHis were 2.68 × 10−7 M, 1.02 × 104 M−1 s−1, and 2.71 × 10−3 s−1, respectively. These 
values are comparable to EcTI binding to recombinant βFXIIHis and the KD, ka and kd values 
were 3.38 × 10−7 M, 8.17 × 103, M−1 s−1, and 2.76 × 10−3 s−1, respectively.  
To understand the molecular basis of the Kunitz-type inhibitor complex with βFXIIa 
we performed molecular docking with the crystal structures of βFXIIaHis and EcTI (pdb code: 
4J2Y) using the program Cluspro (Kozakov et al., 2017). Inspection of the top ranked 
docking solution identified a canonical complex whereby the EcTI residue Arg64 was 
inserted into the S1 pocket of βFXIIaHis with scores of -769.4 and -962.1, representing centre 
and lowest energy scores, respectively, for 274 members in the largest cluster size (the second 
























































































Fig. 6A,B shows a cartoon diagram of the predicted βFXIIaHis-EcTI complex and Fig. 
6C a surface charge distribution of βFXIIaHis with EcTI as a cartoon diagram. Table S1 lists 
the key electrostatic and hydrogen bond interactions at the interface, burying a total surface 
area of 1207 Å2 (pdbe-PISA) in comparison to 988 Å2 observed in the trypsin-EcTI complex 
(pdb code: 4J2K). The EcTI Arg64 side-chain extends into the S1 pocket of the FXIIa 
catalytic domain forming a salt bridge with the S1 pocket residue Asp189 side-chain carboxyl 
(chymotrypsin numbering used) (Fig. 6B). Additional interactions flanking the P1 Arg64 
include Pro63 interacting with the S2 pocket (Fig. 6D) which is similar to interactions 
observed in the MBP-βFXIIaHis-PPACK complex.  
 
3.7 P2 substrate preference of βFXIIa 
FXIIa cleaves three substrates FXII, PK, FXI and substrate selection is driven by a 
combination of exosite and subsite interactions that are poorly understood. An alignment of 
the sequences in the area of the cleavage site is shown in Table 3. All have Arg at the P1 
position, but at the P2 position there is greater variability as FXI has Pro and FXII, PK both 
have a Thr residue. High throughput protease specificity profiling using a diverse short 
peptide based fluorogenic substrate microarray confirmed the requirement of Arg at P1 and 
revealed a FXIIa preference for Phe and Thr at the P2 position, which is consistent with the 
sequence Pro-Phe-Arg of the widely used FXIIa substrate S-2302 (Gosalia et al., 2006, Zhou 
et al., 2013). Table 3 shows FXII inhibitors follow this preference for Phe and Thr at the P2 
position (PCK, infestin-4, and bicyclic peptide (Middendorp et al., 2017)) and also mimic its 
substrate FXI with Pro in the P2 (CTI and EcTI). This more open S2 pocket observed in both 
MBP-βFXIIaHis and βFXIIaHis presents a framework that explains the FXIIa substrate 
preference for a bulky Phe sidechain at the P2 position. Why the natural substrates utilise Thr 
at P2 more commonly and do not utilise Phe at P2 is unclear, but as discussed below, it is 


























































































3.7 Docking of βFXIIaHis with Infestin-4  
 The exogenous inhibitor Infestin-4 is derived from the blood sucking kissing bug and 
has been characterised in detail as a FXIIa inhibitor which has also been optimised for 
selectivity. Previous studies have performed docking on Infestin-4 using a model of FXIIa 
and presented a complex which places the Infestin-4 P2 Phe9 sidechain in the S1' pocket and 
the P1' Asn11 in the S2 pocket (Kolyadko et al., 2015). A crystal structure of Infestin-4 was 
utilised in docking simulations with the βFXIIaHis crystal structure. Figure 7 shows the highest 
scoring complex with the Infestin-4 P1 Arg and P2 Phe inserted into the βFXIIaHis S1 and S2 
pocket respectively. Interestingly three highly complementary salt bridges are formed 
between infestin-4 residues Lys36, Lys21 and Arg40 with βFXIIaHis residues Asp222 from 
220-loop and E151B, E151E from the 140-loop, respectively. This orientation is the reverse 
of the Kolyadko et al., 2015 Infestin-4:FXIIa docked complex and highlights the importance 




Efforts are currently underway to design selective inhibitors for FXIIa as novel 
treatments for thrombotic and inflammatory disorders (Middendorp et al., 2017, Kolyadko et 
al., 2015, Krupka et al., 2016, Campos et al., 2012). To investigate the FXIIa protease 
structure in complex with peptidomimetic inhibitors we developed vectors and an insect cell 
based protocol for recombinant expression and purification of the βFXIIa protease domain 
achieving yields suitable for enzyme kinetic and protein crystallography experiments. MBP-
βFXIIaHis crystals were obtained through co-crystallization experiments with the PPACK 
inhibitor. PPACK is a selective inhibitor of thrombin and a comparison of the PPACK-MBP-
























































































the PPACK P3 Phe residue forms interactions with residues in the S3 pocket in the thrombin 
complex, whereas in the MBP-βFXIIaHis complex the Phe residue is projecting outwards and 
not forming significant interactions with contacts exclusively through the PPACK Arg and 
Pro residues which is reminiscent of the FIXa-PPACK complex (Kristensen et al., 2016).  
A second construct βFXIIaHis crystallized in the absence of an inhibitor, but here the 
active conformation was stabilized by Thr-Arg residues from an adjacent molecule in the 
crystal. This Thr-Arg sequence mimics the natural FXIIa substrate P1-P2 cleavage site 
residues present in prekallikrein and FXII activation loop sequences. Previous studies 
utilizing tripeptide substrates have determined the FXIIa optimal residues at P2 to be Phe or 
Thr, and the substrate S-2302 widely used to monitor FXIIa activity has the sequence Pro-
Phe-Arg. The MBP-βFXIIaHis-PPACK (Pro-Arg) and βFXIIaHis-Thr-Arg substrate mimetic 
structures reveal that the Tyr99 residue alters its position from packing against His57 
(observed in the zymogen FXIIc structure), which effectively opens up the S2 pocket. This 
movement of Tyr99 comes at the expense of the S3 pocket, which is partially occluded by 
packing of Tyr99 against Trp215.  
Infestin-4 and a bicyclic peptide are selective protein/peptide based inhibitors of 
FXIIa which both utilise Phe residue at the P2 position (Middendorp et al., 2017, Kolyadko et 
al., 2015, Krupka et al., 2016, Campos et al., 2012). The more open S2 pocket provides a 
model for the preference of the bulky Phe residue at P2 and future studies involving a crystal 
structure with bound substrate mimetic or exogenous inhibitor will be required to demonstrate 
how this pocket is utilised. A series of crystal structures have been reported for protease 
domains that have a similar S2 pocket and residue Tyr99 (FXa, tPa and FIXa), however, most 
of these have the closed configuration of S2 with Tyr99 packing against His57, implying this 
transiently opens only in the presence of a substrate mimetic. A comparison of the 
recombinant βFXIIaHis-Thr-Arg structure with the benzamidine-βFXIIa structure reveals the 
























































































The role of the distinctive negatively charged ridges in the 140 and 220-loops 
observed surrounding the FXII active site is unknown(Pathak et al., 2015), but the substrates 
FXI (Mohammed et al., 2018), PK (Hooley et al., 2007) and the natural inhibitor serpin C1 
inhibitor have positively charged residues (Huntington, 2011, Beinrohr et al., 2007, Hamad et 
al., 2017) that may provide electrostatic interactions with βFXIIa. Overall, these βFXIIa 
structures provide a framework to understand substrate selectivity and for rational design of 
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Figure 1. FXII domain organization and protein expression construct designs.  Schematic 
representation of the FXII domain organization (top) with the disulfide bridge (Cys340-
Cys467) between heavy chain and catalytic domain is shown. The principal activating 
cleavage site is depicted as an arrow between residues Arg353-Val354. Other cleavage sites 
are depicted with Arg334-Asn335 resulting in the formation of βFXIIa. Below this is the 
MBP-βFXIIaHis and βFXIIaHis constructs used to generate recombinant βFXIIa. HCR denotes 


































































































































































































Figure 2. Structure of βFXIIaHis. (a) Cartoon diagram of the βFXIIaHis active site is shown 
occupied by four amino acids (sticks colored orange) from the C-terminus of an adjacent 
molecule in the crystal. Thr1-Arg2 are numbered thus as they are not derived from the FXII 
sequence but from the C-terminal regions of the expression construct. Residues from the S2 
pocket are shown as sticks in green and S3 in cyan. (b) A close up of the structure in A shown 
with electrostatic interactions between V-S-T-R residues and residues from the βFXIIaHis S1, 
S2 and S3 pockets illustrated as purple dotted lines. (c) Cartoon diagram of βFXIIaHis (grey) 
superposed onto the FXIIc structure (purple) with key loops altering conformation labeled 
(140-loop represents residues in the range of residue 140 using chymotrypsin numbering 
which is also known as the autolysis loop). (d) Surface representation of the S2 and S3 
pockets in a similar view as shown in B. Close contact of the Tyr99 hydroxyl with the V-S-T-
R main chain carbonyl is shown as a yellow dotted line. (e) The S2 pocket in βFXIIaHis with 
V-S-T-R residues (orange sticks) is shown superposed onto the FXIIc structure (purple) 




























































































Figure 3. Changes in the overall surface charge distribution in the βFXIIaHis structure 
compared to the zymogen like FXIIc structure. (a) Electrostatic (red=negative; blue= positive) 
charge distribution in both βFXIIa (right) and FXIIc (left) with a large movement of the ridge 
of negative charge labeled R2 is shown. (b) Cartoon diagram showing the distribution of 
























































































































































































Figure 4. Structure of the MBP-βFXIIaHis crystal structure complexed with PPACK. (a) 
Cartoon representation of the crystal structure of the MBP-βFXIIaHis-PPACK complex. MBP 
shown in dark green and βFXIIaHis in rainbow with HCR indicated and N-linked glycan 
residues as sticks in orange and PPACK (purple). The maltose bound to MBP is drawn in ball 
and stick in yellow. (b) Ribbon diagram of the interactions occurring at the interface between 
MBP and the βFXIIaHis fusion partner. The interacting residues are drawn in sticks with 
electrostatic interactions depicted as dashed lines. (c) Detailed interactions of PPACK (black) 
with key residues shown as sticks forming interactions with the S1 pocket (dashed lines). The 
dotted circle shows the oxyanion hole and Asp189 residue forming the base of the S1 pocket 
is also shown. (d) MBP-βFXIIaHis protease surface charged representation (negative=red, 

































































































Figure 5. βFXIIa binding to kunitz type inhibitor EcTI. (a) The βFXIIaHis-EcTI complex was 
analyzed by gel filtration. Arrows numbered 1, 2, and 3 indicate the elution volume of 
molecular weight standards of 43 kDa, 22 kDa and 13.7 kDa respectively. The panel on the 
left shows the coomassie stained SDS-PAGE gel under reducing conditions with different 
lanes representing eluted fractions from gel filtration of the βFXIIaHis-EcTI complex. (b) SPR 
analysis showing the commercial βFXIIa (left) and recombinant βFXIIaHis (right) binding to 
EcTI. SPR sensorgrams illustrate the βFXIIa interactions with immobilized EcTI at various 
βFXIIa concentrations. The arrow indicates increasing βFXIIa concentrations used at 0, 





































































































Figure 6. Molecular docking of the inhibitor EcTI with βFXIIaHis. (a) Cartoon representation 
of the Cluspro docked complex of βFXIIaHis (blue) with EcTI (pink) shown as two rotated 
views with interfacial residues as sticks. (b) Close up view of the interface between EcTI and 
βFXIIaHis with the interacting residues drawn in sticks and electrostatic interactions as dashed 
lines. (c) Charged surface representation of βFXIIaHis with a cartoon representation of the 
docked EcTI structure (orange). (d) Zoomed in view of the charged surface representation of 


































































































Figure 7. Molecular docking of the Infestin-4 crystal structure (pdb code:2ERW) with 
βFXIIaHis. (a) Cartoon representation of the Cluspro docked complex of βFXIIaHis (grey) with 
Infestin-4 (cyan) shown as two rotated views with interfacial residues as sticks. (b) Close up 
view of the interface between Infestin-4 and βFXIIaHis with the interacting residues drawn in 








































































































Table 1. Enzyme kinetic parameters for FXIIa samples cleaving substrate S-2302 
 
 




  Km 
(mM)  
  kcat/ Km  
(L mol-1 s-1) 
MBP-βFXIIaHis 24.40±0.60 17.43±0.83 0.10±0.02 174300 
βFXIIaHis 32.93±2.70 21.75±1.86 0.20±0.04 108750 
βFXIIa  34.20±3.24 24.44±0.75 0.16±0.01 101880 
αFXIIa  21.72±1.04 15.52±0.74 0.17±0.02 91294 
 
 
Values are reported with standard error of the regression analysis calculated with GRAPHPAD PRISM 



























































































Table 2. Data collection and refinement statistics 
 MBP-βFXIIaHis PPACK βFXIIaHis 
Data Collection   
Space group P 41 21 2  P 41 21 2  
Unit cell dimensions                        
a, b, c (Å) 131.5, 131.5, 238.4 106.9, 106.9, 66.0     
α, β, γ (°)                             90, 90, 90                              90, 90, 90 
Wavelength (Å)                    0.9795 0.97951  
Resolution (Å)                      4.0 2.54  
Rmerge                                  0.189 (0.468) 0.218 (0.821) 
I/σI                                           3.8 (1.7) 5.6 (1.7) 
Completeness (%)                 94.8 (95.7) 99.9 (100) 
Multiplicity                              2.5 6.3       
CC ½                                       0.95 (0.61) 0.985 (0.35)  
Unique reflections                17015 (4810)  13131 (938) 
Refinement   
Rwork                                         0.297 (0.368)  0.213(0.219)                                 
Rfree                                          0.356 (0.401)  0.265 (0.269)                                
 B-factor (A2)               38.3 42.0 
Stereo chemical r.m.s.d.   
    Bond length (Å)                 0.011 0.010 
    Bond angle (°)                  1.487 1.439 
Ramachandran plot   
  Most favored (%)   91.2  95.26        
   Allowed (%)                         8.8    4.74                                      
  Outliers (%)                        0.0 0.0                                        


































































































  P3P2P1P1′P2′  
Substrates 
PK 
   S T R I V 
FXII
   M T R V V 
FXI 
   K P R I V 
Inhibitors 
PCK 
   P F R   
Infestin-4 
   C F R N Y 
Infestin-4mB 
   C T R N F 
CTI 
   G P R L P 
Bicyclic-pep   
   C F R L P 
EcTI  
   P P R I A 
PPACK
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Figure S1. (a) Recombinant and plasma purified βFXIIa crystal structures compared. C-α 
traces are displayed for superposed recombinant protease domain βFXIIaHis (grey) and plasma 
purified βFXIIa  (pdb code:6b74, orange) generated using PyMol and overall r.m.s.d. for the 
superposition=0.513 Å (b) Zoomed in view illustrating key differences in the region of the 






























































































Figure S2. Plot of enzyme substrate S2302 hydrolysis as function of substrate concentration 
for recombinant MBP-βFXIIaHis, commercial βFXIIa and commercial αFXIIa. OD at 405 nm 
(as a function of time (min)) for different concentrations of S2302 added to βFXIIa was used 
to calculate initial rate (pmols-1) of S2302 hydrolysis (left panel). An average of four 
experiments were used to determine the enzyme kinetics with independent plots superposed 


































































































Figure S3. Cartoon diagram of the MBP-βFXIIaHis structure. MBP and βFXIIaHis are shown 
in blue and cyan respectively. A, Electron density 2Fo-Fc maps at 4 Å resolution are 
contoured at 1.0 σ are shown (green) for the bound maltose and N-linked glycan. B. Electron 
density Fo–Fc difference map showing the position of PPACK in the βFXIIaHis active site 
cleft. Side chains interacting with PPACK and the catalytic triad are drawn as sticks. C, 
Electron density 2Fo-Fc maps at 2.54 Å resolution are shown contoured at 1.0 σ (grey) for 
βFXIIaHis in the region of the N-terminus and D shows the S1 pocket with crystal symmetric 
































































































  βFXIIa  [atom]  Dist. [Å]   EcTI [atom] 
Hydrogen Bonds 
1 GLN 192[NE2]   2.91  ASN13[ O  ] 
2  TYR 99[OH]   2.79  THR 61[ OG1] 
3  GLY 215[N]   3.18  PRO62[ O] 
4  GLY 193[N]   2.71  ARG64[ O] 
7  SER 177[OG]   2.77  HIS114[ O] 
11  SER 214[O]   3.24  ARG64[ N ] 
17  GLN 60[OE1]   2.83  THR69[OG1] 
Salt Bridges 
1  GLU 149[OE2]   3.45  ARG12[NH1] 
2  GLU 149[OE1]   2.74  ARG12[NH1] 
3  GLU 149[OE2]   2.81  ARG12[NH2] 
4  GLU 149[OE1]   2.73  ARG12[NH2] 
5  ASP 189[OD1]   2.73  ARG64[NH1] 
6  ASP 189[OD2]   3.69  ARG64[NH1] 
7  ASP 189[OD1]   3.18  ARG64[NH2] 
8  ASP 189[OD2]   2.73  ARG64[NH2] 
9  ASP 222[OD2]   3.95 ARG92[NE ] 
10  ASP 222[OD2]   2.76  ARG92[NH1] 
11  GLU 146[OE1]   3.11  ARG92[NH1] 
12  GLU 146[OE1]   3.8  ARG92[NH2] 
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